Vilon

Vilon is a synthetic dipeptide (Lys-Glu, KE) classified as a Khavinson-class bioregulator originally derived from thymic tissue, proposed to modulate immune function in aging subjects by providing minimal thymic regulatory dipeptide signals that support T-lymphocyte activation and immune homeostasis diminished by age-related thymic involution. As the minimal active dipeptide unit of the Khavinson thymic bioregulator class, vilon is proposed to act through amino acid transporter uptake and modulation of intracellular signaling — including sphingomyelin pathway signal transduction in thymocytes — to restore T-cell activation thresholds and proliferative responses in immune cells from elderly subjects.

immune modulation, anti-aging, immune restoration, Longevity.

Research on Vilon primarily documents effects related to immune modulation and anti-aging and immune restoration and Longevity. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Vilon, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

1 provider in the directory currently offers Vilon.

Vilon is tracked across 1 research vendor on PeptideBase, at about $2.75 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

Research in mouse thymocyte cultures found that vilon produced the most potent comitogenic stimulation of thymocyte proliferation and sphingomyelinase activity compared with epithalon and cortagen, providing mechanistic evidence for its thymopoiesis-promoting activity and relevance to immune restoration in aging.